Spero Therapeutics, Inc. (SPRO)

Over the past six months, Spero Therapeutics' stock has been impacted by several events. In August 2025, the company reported positive Q2 financial results and the early termination of the PIVOT-PO Phase 3 trial for tebipenem HBr. In October 2025, positive Phase 3 data for tebipenem HBr were announced. In November 2025, the company reported its Q3 operating results and a business update. In December 2025, GSK filed an NDA resubmission for tebipenem HBr, triggering a milestone payment to Spero. In January 2026, Ankit Mahadevia resigned from the Board of Directors, and the SEC concluded its investigation into the company. In February 2026, Spero Therapeutics shares surged following news that GSK expects regulatory approval for tebipenem in 2026, and insider selling by CEO Esther Rajavelu was reported.

The provided information does not indicate any specific demand seasonality for Spero Therapeutics' products or services. Demand for its potential future products is typically driven by disease prevalence and medical need rather than seasonal patterns.

Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel treatments for rare diseases and multidrug-resistant bacterial infections. Their pipeline includes Tebipenem HBr, an oral carbapenem-class antibiotic in Phase 3 development for complicated urinary tract infections; SPR206, an intravenous antibiotic in Phase 2 development targeting MDR Gram-negative bacterial infections; and SPR720, an oral antibiotic agent whose development was suspended after failing to meet primary endpoints. The company has strategic collaborations with Meiji Seika Pharma Co., Ltd. and Everest Medicines.

Spero Therapeutics is headquartered in Cambridge, Massachusetts, United States. Its market reach extends internationally through licensing agreements, with Meiji Seika Pharma Co., Ltd. holding rights for tebipenem HBr in Japan and other Asian countries, and Everest Medicines covering Greater China, South Korea, and Southeast Asian countries for SPR206.

Spero Therapeutics' brand reputation has been influenced by positive developments and historical regulatory scrutiny. Positive Phase 3 trial results for tebipenem HBr and its NDA resubmission by GSK have bolstered the company's standing, and the expectation of regulatory approval for tebipenem in 2026 contributes to a positive outlook. However, the company's reputation faced scrutiny due to an SEC settlement with two former executives regarding misleading statements in 2022, though the SEC concluded its investigation into the company itself without recommending enforcement action.

Spero Therapeutics, Inc. has a diverse ownership structure. Retail investors hold the largest stake at 54%, while institutions collectively own 20% of the company. Major institutional owners and shareholders include Pfizer Inc., Vanguard Group Inc., Anson Funds Management LP, Renaissance Technologies Llc, Alphabet Inc., Geode Capital Management, Llc, BlackRock, Inc., SR One Capital Management, LP, Pfizer Venture Investments LLC and GV Management Company, LLC.